DB
PBYI icon

Dmitry Balyasny’s Puma Biotechnology PBYI Stock Holding History

Dmitry Balyasny’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200,000
Closed -$9.56M – 1658
2018
Q3 		$9.56M Buy
200,000
+182,800
+1,063% +$8.81M 0.04% 506
2018
Q2 		$1.02M Buy
+17,200
New +$997K ﹤0.01% 1124

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's PBYI Position: Q2 2024 in Review

Dmitry Balyasny sold out of Puma Biotechnology (PBYI) in Q2 2024, closing a stake of 32,709 shares — an estimated $173K sold.

Dmitry Balyasny first reported a position in PBYI in Q2 2013 and held it in 17 quarters. The position peaked at $22.5M in Q3 2017. 99 funds tracked by Wall St. Rank hold PBYI as of Q2 2024.

  • Dmitry Balyasny reported no remaining Puma Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 32,709 Puma Biotechnology shares in Q2 2024, an estimated $173K.
  • Dmitry Balyasny first reported a position in Puma Biotechnology in Q2 2013 and held it in 17 quarters.
  • Dmitry Balyasny's Puma Biotechnology position peaked at $22.5M in Q3 2017.
  • 99 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.